Compare BNTC & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNTC | PSBD |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 386.6M |
| IPO Year | N/A | 2024 |
| Metric | BNTC | PSBD |
|---|---|---|
| Price | $12.91 | $12.22 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 5 |
| Target Price | ★ $26.00 | $13.30 |
| AVG Volume (30 Days) | ★ 230.7K | 67.1K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 13.93% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.70 | $11.51 |
| 52 Week High | $17.15 | $16.16 |
| Indicator | BNTC | PSBD |
|---|---|---|
| Relative Strength Index (RSI) | 44.48 | 47.97 |
| Support Level | $12.78 | $12.15 |
| Resistance Level | $13.68 | $12.41 |
| Average True Range (ATR) | 0.75 | 0.23 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 59.35 | 62.32 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.